Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy

NCT01949194 is registered in ClinicalTrials.gov with Gerald Batist as lead sponsor.

NCT NCT01949194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01949194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy
Lead sponsor
Gerald Batist
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2013
Completion date
December 31, 2018
Enrollment
48 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer